Professional paper - Letter to the editor
Why we should not recommend or offer fluvoxamine to COVID-19 patients?
European Journal of Clinical Pharmacology, 79 (2023), 2; 321-322. https://doi.org/10.1007/s00228-022-03447-3


Cite this document

Trkulja, V. (2023). Why we should not recommend or offer fluvoxamine to COVID-19 patients?. European Journal of Clinical Pharmacology, 79. (2), 321-322. doi: 10.1007/s00228-022-03447-3

Trkulja, Vladimir. "Why we should not recommend or offer fluvoxamine to COVID-19 patients?." European Journal of Clinical Pharmacology, vol. 79, no. 2, 2023, pp. 321-322. https://doi.org/10.1007/s00228-022-03447-3

Trkulja, Vladimir. "Why we should not recommend or offer fluvoxamine to COVID-19 patients?." European Journal of Clinical Pharmacology 79, no. 2 (2023): 321-322. https://doi.org/10.1007/s00228-022-03447-3

Trkulja, V. (2023) 'Why we should not recommend or offer fluvoxamine to COVID-19 patients?', European Journal of Clinical Pharmacology, 79(2), pp. 321-322. doi: 10.1007/s00228-022-03447-3

Trkulja V. Why we should not recommend or offer fluvoxamine to COVID-19 patients?. European Journal of Clinical Pharmacology [Internet]. 2023 February [cited 2024 November 26];79(2):321-322. doi: 10.1007/s00228-022-03447-3

V. Trkulja, "Why we should not recommend or offer fluvoxamine to COVID-19 patients?", European Journal of Clinical Pharmacology, vol. 79, no. 2, pp. 321-322, February 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:779915. [Accessed: 26 November 2024]